Using  	Using  	 VBG	B-NP
non-steroidal  	non-steroidal  	 JJ	I-NP
anti-inflammatory  	anti-inflammatory  	 JJ	I-NP
drugs  	drugs  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
depression  	depression  	 NN	B-NP
clinicians  	clinicians  	 NNS	I-NP
have  	have  	 VBP	O
long  	long  	 RB	O
noticed  	noticed  	 VBD	O
a  	a  	 DT	O
correlation  	correlation  	 NN	O
between  	between  	 IN	O
physiological  	physiological  	 JJ	B-NP
markers  	markers  	 NN	I-NP
of  	of  	 IN	I-NP
inflammation  	inflammation  	 NN	I-NP
and  	and  	 CC	O
depression 	depression 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
best-known  	best-known  	 JJS	O
example  	example  	 NN	O
is  	is  	 VBZ	O
the  	the  	 DT	O
activation  	activation  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
hypothalamus-pituitary-adrenal  	hypothalamus-pituitary-adrenal  	 JJ	I-NP
axis  	axis  	 NN	I-NP
and  	and  	 CC	O
cortisol  	cortisol  	 JJ	B-NP
secretion 	secretion 	 NN	I-NP
;  	;  	 :	O
however  	however  	 RB	O
more  	more  	 RBR	O
recent  	recent  	 JJ	O
studies  	studies  	 NNS	O
have  	have  	 VBP	O
demonstrated  	demonstrated  	 VBN	O
increased  	increased  	 VBN	O
salivary  	salivary  	 JJ	B-NP
prostaglandins  	prostaglandins  	 NN	I-NP
and  	and  	 CC	O
plasma  	plasma  	 JJ	B-NP
acute  	acute  	 JJ	O
phase  	phase  	 NN	O
proteins  	proteins  	 NNS	O
in  	in  	 IN	O
depressed  	depressed  	 JJ	O
patients 	patients 	 NNS	O
.  	.  	 .	O
To  	To  	 TO	O
date  	date  	 VB	O
four  	four  	 CD	O
randomised  	randomised  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trials  	trials  	 NNS	I-NP
have  	have  	 VBP	O
used  	used  	 VBN	O
celecoxib  	celecoxib  	 NNS	B-NP
or  	or  	 CC	O
rofecoxib  	rofecoxib  	 NN	B-NP
as  	as  	 IN	O
adjuncts  	adjuncts  	 VBG	B-NP
to  	to  	 TO	O
serotonin  	serotonin  	 VB	O
selective  	selective  	 JJ	B-NP
reuptake  	reuptake  	 JJ	I-NP
inhibitors  	inhibitors  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
depression 	depression 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
suggested  	suggested  	 VBD	O
a  	a  	 DT	O
statistically  	statistically  	 JJ	O
significant  	significant  	 JJ	O
decrease  	decrease  	 NN	O
in  	in  	 IN	O
depressive  	depressive  	 JJ	B-NP
symptoms  	symptoms  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
taking  	taking  	 VBG	O
NSAIDs  	NSAIDs  	 JJ	O
and  	and  	 CC	O
SSRIs 	SSRIs 	 JJ	O
,  	,  	 ,	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
patients  	patients  	 NNS	O
taking  	taking  	 VBG	O
SSRIs  	SSRIs  	 JJ	O
alone 	alone 	 RB	O
.  	.  	 .	O
Interpretation  	Interpretation  	 NN	B-NP
of  	of  	 IN	O
these  	these  	 DT	O
results  	results  	 NNS	O
is  	is  	 VBZ	O
limited  	limited  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
small  	small  	 JJ	O
sample  	sample  	 NN	O
size  	size  	 NN	O
and  	and  	 CC	O
short  	short  	 JJ	O
duration  	duration  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
preliminary  	preliminary  	 JJ	B-NP
studies 	studies 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
research  	research  	 NN	O
only  	only  	 RB	O
considers  	considers  	 VBZ	O
depressed  	depressed  	 JJ	O
patients  	patients  	 NNS	O
receiving  	receiving  	 VBG	B-NP
treatment  	treatment  	 NN	I-NP
in  	in  	 IN	O
secondary  	secondary  	 JJ	B-NP
care 	care 	 NN	I-NP
;  	;  	 :	O
no  	no  	 DT	O
study  	study  	 NN	O
has  	has  	 VBZ	O
examined  	examined  	 VBN	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
NSAIDs  	NSAIDs  	 JJ	O
as  	as  	 IN	O
an  	an  	 DT	O
adjunct  	adjunct  	 NN	B-NP
in  	in  	 IN	O
primary  	primary  	 JJ	B-NP
care 	care 	 NN	I-NP
,  	,  	 ,	O
even  	even  	 RB	O
though  	though  	 IN	O
most  	most  	 JJS	O
cases  	cases  	 NNS	O
of  	of  	 IN	O
depression  	depression  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
UK  	UK  	 NNP	B-NP
are  	are  	 VBP	O
managed  	managed  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
community  	community  	 NN	O
by  	by  	 IN	O
general  	general  	 JJ	O
practitioners.  	practitioners.  	 NN	B-NP
we  	we  	 PRP	O
propose  	propose  	 VBP	O
a  	a  	 DT	O
multi-centre  	multi-centre  	 JJ	B-NP
double-blinded  	double-blinded  	 JJ	O
randomised  	randomised  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trial  	trial  	 NN	I-NP
with  	with  	 IN	O
two  	two  	 CD	O
objectives 	objectives 	 NNS	O
:  	:  	 :	O
to  	to  	 TO	O
determine  	determine  	 VB	O
whether  	whether  	 IN	O
citalopram  	citalopram  	 NN	B-NP
plus  	plus  	 CC	O
celecoxib  	celecoxib  	 JJ	B-NP
dual  	dual  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
achieves  	achieves  	 VBZ	O
a  	a  	 DT	O
greater  	greater  	 JJR	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
depressive  	depressive  	 JJ	B-NP
symptoms  	symptoms  	 NNS	I-NP
( 	( 	 -LRB-	O
quantified  	quantified  	 VBN	O
using  	using  	 VBG	O
the  	the  	 DT	O
Hamilton  	Hamilton  	 NNP	B-NP
Depression  	Depression  	 NNP	I-NP
Rating  	Rating  	 NNP	I-NP
Scale  	Scale  	 NNP	I-NP
( 	( 	 -LRB-	O
HDRS 	HDRS 	 NNP	B-NP
) 	) 	 -RRB-	O
)  	)  	 -RRB-	O
within  	within  	 IN	O
four  	four  	 CD	O
weeks 	weeks 	 NNS	O
,  	,  	 ,	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
citalopram  	citalopram  	 VB	O
monotherapy 	monotherapy 	 NNS	B-NP
;  	;  	 :	O
and  	and  	 CC	O
to  	to  	 TO	O
determine  	determine  	 VB	O
whether  	whether  	 IN	O
citalopram  	citalopram  	 NN	B-NP
plus  	plus  	 CC	O
celecoxib  	celecoxib  	 JJ	B-NP
dual  	dual  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
is  	is  	 VBZ	O
more  	more  	 RBR	O
likely  	likely  	 JJ	O
to  	to  	 TO	O
achieve  	achieve  	 VB	O
remission  	remission  	 NNS	O
( 	( 	 -LRB-	O
HDRS  	HDRS  	 NNP	B-NP
score  	score  	 NN	I-NP
? 	? 	 CD	O
7 	7 	 CD	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
moderate  	moderate  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
depression  	depression  	 NN	O
within  	within  	 IN	O
six  	six  	 CD	O
months 	months 	 NNS	O
,  	,  	 ,	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
citalopram  	citalopram  	 JJ	B-NP
monotherapy 	monotherapy 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
endpoints  	endpoints  	 NN	B-NP
will  	will  	 MD	O
be  	be  	 VB	O
the  	the  	 DT	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
HDRS  	HDRS  	 NNP	B-NP
score  	score  	 NN	I-NP
after  	after  	 IN	O
4  	4  	 CD	O
weeks  	weeks  	 NNS	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
HDRS  	HDRS  	 NNP	B-NP
score  	score  	 NN	I-NP
after  	after  	 IN	O
26  	26  	 CD	O
weeks  	weeks  	 NNS	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
study  	study  	 NN	O
will  	will  	 MD	O
enrol  	enrol  	 VB	O
452  	452  	 CD	O
participants  	participants  	 NNS	B-NP
from  	from  	 IN	O
general  	general  	 JJ	O
practices  	practices  	 NNS	O
who  	who  	 WP	O
have  	have  	 VBP	O
a  	a  	 DT	O
moderate  	moderate  	 JJ	O
or  	or  	 CC	O
severe 	severe 	 JJ	O
,  	,  	 ,	O
current  	current  	 JJ	O
or  	or  	 CC	O
recurrent  	recurrent  	 JJ	O
major  	major  	 JJ	O
depressive  	depressive  	 JJ	B-NP
episode  	episode  	 NN	I-NP
when  	when  	 WRB	O
medication  	medication  	 NN	O
with  	with  	 IN	O
an  	an  	 DT	O
SSRI  	SSRI  	 NNP	B-NP
is  	is  	 VBZ	O
considered 	considered 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
study  	study  	 NN	B-NP
population  	population  	 NN	I-NP
will  	will  	 MD	O
be  	be  	 VB	O
stratified  	stratified  	 VBN	O
according  	according  	 VBG	O
to  	to  	 TO	O
age 	age 	 NN	O
,  	,  	 ,	O
sex 	sex 	 NN	O
,  	,  	 ,	O
HDRS  	HDRS  	 NNP	B-NP
score 	score 	 NN	I-NP
,  	,  	 ,	O
age  	age  	 NN	O
of  	of  	 IN	O
onset  	onset  	 NN	O
of  	of  	 IN	O
first  	first  	 JJ	O
episode 	episode 	 NN	O
,  	,  	 ,	O
number  	number  	 NN	O
of  	of  	 IN	O
previous  	previous  	 JJ	O
depressive  	depressive  	 JJ	B-NP
episodes  	episodes  	 NNS	I-NP
and  	and  	 CC	O
duration  	duration  	 NN	O
of  	of  	 IN	O
current  	current  	 JJ	O
episode 	episode 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
population  	population  	 NN	O
will  	will  	 MD	O
then  	then  	 RB	O
be  	be  	 VB	O
randomised  	randomised  	 VBN	O
into  	into  	 IN	O
two  	two  	 CD	O
groups 	groups 	 NNS	O
.  	.  	 .	O
Subjects  	Subjects  	 NNS	B-NP
will  	will  	 MD	O
be  	be  	 VB	O
interviewed  	interviewed  	 VBN	O
to  	to  	 TO	O
determine  	determine  	 VB	O
HDRS  	HDRS  	 JJ	B-NP
score 	score 	 NN	I-NP
,  	,  	 ,	O
measure  	measure  	 NN	B-NP
blood  	blood  	 NN	I-NP
pressure 	pressure 	 NN	I-NP
,  	,  	 ,	O
count  	count  	 NN	B-NP
pills  	pills  	 NNS	I-NP
and  	and  	 CC	O
discuss  	discuss  	 VB	O
side-effects 	side-effects 	 JJ	B-NP
.  	.  	 .	O
This  	This  	 DT	O
will  	will  	 MD	O
occur  	occur  	 VB	O
weekly  	weekly  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
four  	four  	 CD	O
weeks 	weeks 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
every  	every  	 DT	O
four  	four  	 CD	O
weeks  	weeks  	 NNS	O
thereafter 	thereafter 	 RB	O
.  	.  	 .	O
